Safety and efficacy of sofosbuvir + GS5816 for 12 Weeks In Treatment Naive Patients with Hepatitis C Virus Genotype 1-6 Infection.

Trial Profile

Safety and efficacy of sofosbuvir + GS5816 for 12 Weeks In Treatment Naive Patients with Hepatitis C Virus Genotype 1-6 Infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 May 2014

At a glance

  • Drugs Sofosbuvir (Primary) ; Velpatasvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 May 2014 New trial record
    • 13 Apr 2014 Results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top